Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery.
For most cancers, survival rates depend on the early detection of the disease. So far, no biomarkers exist to cope with this difficult task. New proteomic technologies have brought the hope of discovering novel early cancer-specific biomarkers in complex biological samples and/or of the setting up of new clinically relevant test systems. Novel mass spectrometry-(MS) based technologies in particular, such as surface-enhanced laser desorption/ionisation time of flight (SELDI-ToF-MS), have shown promising results in the recent literature. Here, proteomic profiles of control and disease states are compared to find biomarkers for diagnosis. This paper aims to address the authors' own work and that of other groups in clinical cancer proteomics based on SELDI-ToF-MS. Shortcomings and hopes for the future are discussed.
EUROPROTEOME AG, Neuendorfstrasse 24b, D-16761 Hennigsdorf, Germany. volkerseibert@yahoo.de
Volker
V
Seibert
Matthias P A
MP
Ebert
Thomas
T
Buschmann
D014408:Biomarkers, Tumor / Q000737:chemistry*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000378:metabolism*; D040081:Protein Array Analysis / Q000379:methods; D040901:Proteomics / Q000379:methods*; D012984:Software; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods*
D014408:Biomarkers, Tumor